Alcon, Inc.
Clinical data on Travatan/Timolol Fixed Combination reported at glaucoma meeting
Published in Pharma Investments, Ventures and Law Weekly, April 11th, 2004
Alcon has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for TTFC, which combines travoprost 0.004% and timolol 0.5% into a once-daily medication.
The data from one study demonstrated that TTFC reduced intraocular pressure (IOP) by up to 12 mmHg. The change in IOP produced by TTFC was 2 mmHg more than that produced by travoprost 0.004% alone at the 8 a.m. time point. At the 10 a.m....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- AVI BioPharma, Inc.
Neugene maker reports quarterly loss of $0.10 per share - Alfacell Corporation
Savadelis named chief financial officer at pharmaceutical firm - Alnylam Pharmaceuticals, Inc.
Isis Pharmaceuticals enters RNAi alliance - American Oriental Bioengineering
Bioengineering firm expects record revenue growth, income for 2003 - Aspreva Pharmaceuticals Corp.
Autoimmune disease drug maker completes raises $57 million - Avitar, Inc.
Diagnostics company announces second closing of private placement - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
